Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Alessia Paganelli
 -- 2351 2023-03-24 07:39:14 |
2 update references and layout
Rita Xu
 Meta information modification 2351 2023-03-24 07:58:45 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Alma, A.; Marconi, G.D.; Rossi, E.; Magnoni, C.; Paganelli, A. Obesity and Wound Healing. Encyclopedia. Available online: https://encyclopedia.pub/entry/42499 (accessed on 16 November 2024).
Alma A, Marconi GD, Rossi E, Magnoni C, Paganelli A. Obesity and Wound Healing. Encyclopedia. Available at: https://encyclopedia.pub/entry/42499. Accessed November 16, 2024.
Alma, Antonio, Guya Diletta Marconi, Elena Rossi, Cristina Magnoni, Alessia Paganelli. "Obesity and Wound Healing" Encyclopedia, https://encyclopedia.pub/entry/42499 (accessed November 16, 2024).
Alma, A., Marconi, G.D., Rossi, E., Magnoni, C., & Paganelli, A. (2023, March 24). Obesity and Wound Healing. In Encyclopedia. https://encyclopedia.pub/entry/42499
Alma, Antonio, et al. "Obesity and Wound Healing." Encyclopedia. Web. 24 March, 2023.
Obesity and Wound Healing
Edit
This entry is adapted from the peer-reviewed paper 10.3390/life13030717

Chronic wounds represent nowadays a major challenge for both clinicians and researchers in the regenerative setting. Obesity represents one of the major comorbidities in patients affected by chronic ulcers and therefore diverse studies aimed at assessing possible links between these two morbid conditions are currently ongoing. In particular, adipose tissue has recently been described as having metabolic and endocrine functions rather than serving as a mere fat storage deposit. In this setting, adipose-derived stem cells, a peculiar subset of mesenchymal stromal/stem cells (MSCs) located in adipose tissue, have been demonstrated to possess regenerative and immunological functions with a key role in regulating both adipocyte function and skin regeneration.

obesity MSC wound healing

1. Introduction

At present, obesity affects 1.7 billion people worldwide [1]. Notably, obesity often leads to a wide range of possible comorbidities, including cardiovascular disorders and diabetes (type 2 diabetes mellitus, T2DM, in particular) [2]. Most of these obesity-related diseases carry an intrinsic risk of developing chronic ulcers and/or causing significant impairment in physiological wound healing. For example, venous insufficiency is the commonest cause of chronic ulcers and is often associated to—and worsened by—obesity. Venous stasis may also determine delayed wound healing because of altered capillary flow due to impaired hydrostatic pressure [3][4][5]. Another frequent cause of chronic ulcers is peripheral artery disease (PAD), which is notably caused by atherosclerosis and therefore is, in turn, associated with obesity and/or T2DM. PAD determines a reduction in oxygen flow and nutrient supply, which are essential for tissue repair, and sometimes leads to the development of arterial ulcers through tissue ischemia. Neuropathy is another relatively common cause of cutaneous ulcers and represent a key driver for the development of chronic wounds in diabetic patients [6].
Not only do obesity and chronic ulcers represent significant health-related issues from a clinical and economic point of view, but they also lead to social and psychological consequences related to body image [7][8].
Obesity is by definition associated with an excess of adipose tissue. Adipose tissue is present in the human body in the form of brown and white adipose tissue (BAT and WAT), which are mainly responsible for thermogenesis and fat storage, respectively. However, brown adipocytes have been shown to possibly appear in WAT in response to specific thermogenic stimuli, therefore suggesting a more dynamic division between BAT and WAT and undermining previously consolidated notions of a static classification of adipose tissue subtypes [9]. Moreover, current research is pointing to adipose tissue as a more complex system, involved in several other physiological and/or pathological processes, including hormone metabolism, inflammation and wound healing [10][11].
Adipocyte dysfunction seems to play a role in obesity and its comorbidities, including chronic ulcers. For example, reduced adiponectin production by adipocytes has been described in obese patients and current evidence suggests a possible correlation with impaired wound healing [12]. At the same time, adipocytes represent a possible source of leukotriene B4, which prevents macrophage M2 polarization, therefore affecting the remodeling phase of wound healing [13]. Adipocyte lipolysis is also essential in wound repair [14], but it is not clear whether significant impairment is present in obese patients. Furthermore, inflammatory mediators and insulin-related signaling proteins, such as leptin and resistin, have been postulated to contribute to delayed wound healing in the setting of obesity [15].
Beyond adipocytes, other cell types are also present in the fibrous septa of the subcutaneous fat (e.g., endothelial cells, fibroblasts, inflammatory cells, etc.). Among these, ADSCs (adipose-derived mesenchymal stromal/stem cells) are of central importance for their role in wound healing. ADSCs are, in fact, adipose-tissue specific mesenchymal stromal/stem cells (MSCs) and are currently widely studied for their regenerative properties [11][16]. ADSCs have recently been demonstrated to be able to replace the dermal compartment and to promote wound re-epithelization [16][17][18][19]. ADSCs also seem to play a key role in the orchestration of the various phases of wound healing [14]. ADSC function is regulated by the tissue microenvironment: obesity, hypoxia and inflammation affect ADSC cellular plasticity and alter their immunophenotypic profile and regenerative functions [20]. In addition, obesity enhances their migratory potential and leads to their accumulation in visceral adipose tissue (VAT) [21].
The most recent findings in the setting of wound healing and obesity, with a special focus on adipose tissue biology (see Figure 1).
Life 13 00717 g001
Figure 1. Obesity-associated alterations: (1) venous insufficiency, (2) atherosclerosis, (3) pro-inflammatory MSC phenotype, (4) adipocyte hypertrophy, (5) glucose intolerance and/or diabetes, (6–8) chronic ulcers.

2. Obesity: Epidemiology and Comorbidities

Obesity is defined by the presence of a body mass index (BMI) ≥ 30 kg/m2, with normal range varying from 18.5 to 24.9 kg/m2. A BMI between 25.0 to 29.9 kg/m2 is considered overweight [22]. Obesity and being overweight are almost invariably caused by excessive caloric intake compared to the necessary amount, which in turns determines fat storage increase and adipocyte hypertrophy [23]. An unhealthy lifestyle is often the leading cause of obesity, but also genetic and epigenetic factors seem to play a very important role [24]. About 30% of the adult population in the world is overweight or obese, with western countries showing the highest prevalence. The Organization for Economic Cooperation and Development (OECD) estimated a prevalence for obesity ranging from 3.7% in Japan up to 38.2% in the US [25]. In the last two decades, the number of obese patients has tripled in Europe, where obesity is estimated to account for 7% of total healthcare costs [26]. However, the prevalence of obesity is nowadays constantly rising, even in developing countries [27][28], and rising childhood obesity rates portend worsening statistics [29].
According to the UK National Audit Office, obesity-related disorders cause significant loss in terms of both working days and deaths, with subsequent direct and indirect costs being estimated at approximately £480,000,000 and £2,150,000,000 per year, respectively [30]. In the U.S, the economic burden for obesity and its comorbidities was estimated to be around $147 billion in 2008 and $126 billion in 2016 [31][32].
Beyond these numbers, a large number of people is currently at risk of becoming obese, including children with familial history of obesity and/or metabolic syndrome, former smokers, lower social classes and older people [33][34][35][36]. As just mentioned, obesity is usually framed in the broader context of metabolic syndrome (or syndrome X), where it is associated with hypertriglyceridemia, atherosclerosis, reduced HDL, hypertension and impaired glucose tolerance [37]. In particular, metabolic syndrome is defined by the presence of three or more of the following criteria: (1) abdominal obesity (waist circumference ≥ 102 cm for men and ≥ 88 cm for women); (2) triglycerides ≥ 150 mg/dL; (3) high-density lipoprotein (HDL) cholesterol < 40 mg/dL for men and < 50 mg/dL for women; (4) systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg and (5) fasting serum glucose ≥ 100 mg/dL [38].
One of the main issues in obese subjects is T2D, which is notably associated with insulin resistance [39][40][41]. Obese subjects also have an increased cardiovascular risk which, like other obesity-related comorbidities, can be explained by lipid accumulation in internal organs. Atherosclerosis, due to lipid accumulation in arterial walls, has got a pivotal role in coronary and cerebrovascular disease [42]. However, obesity also leads to increased platelet activation, which is responsible for thrombosis and subsequent further inflammation, increasing the likelihood of developing ischemic complications [40]. Triglyceride accumulation in the liver causes non-alcoholic fatty liver disease [43]. Moreover, obesity is a well-established risk factor for cholelithiasis due to cholesterol gallstones [44].
Obesity is also associated with a large variety of other possible comorbid conditions, including endocrine, oncological neurological, dermatological, respiratory and psychological disorders. Alterations in the hypothalamic–pituitary–gonadal (HPG) axis are often present in obese subjects [44]. In particular, polycystic ovary syndrome (PCOS) is strictly connected with metabolic syndrome, and weight loss is often part of the therapeutic regimen [45]. Obesity also carries a higher risk of developing several types of malignancies, such as colorectal, gastric, liver and gallbladder, endometrial and esophageal cancer [46].
As for the neurological complications, obese patients are more likely to develop small fiber sensory neuropathy (SFSN) [47] and recent studies suggest a higher risk of developing a form of cortical atrophy similar to Alzheimer’s disease (AD) [48].
Ulcers, lymphedema, intertrigo, hidradenitis suppurativa, striae distensae, skin tags, acanthosis nigricans, psoriasis, acne, hirsutism and androgenetic alopecia are the main skin condition connected to obesity and metabolic syndrome [49].
Biomechanical stress caused by a high body mass is responsible for numerous comorbidities of the musculoskeletal, respiratory, gastrointestinal and skin systems [44].
From a respiratory point of view, obesity finally increases the risk of obstructive sleep apnea syndrome (OSAS), chronic obstructive pulmonary disease (COPD) and asthma [50]. Even if not universally accepted, obesity is also associated with psychiatric/psychological conditions, including anxiety and depression [51].
Most of the aforementioned comorbidities are associated with the low-grade inflammation which nearly invariably comes with obesity. In fact, adipocytes can produce proinflammatory cytokines, such as IL-6, therefore maintaining the pro-inflammatory state typical of obese subjects, as also confirmed by elevated levels of c-reactive protein (CRP) in these patients [52][53]. This chronic inflammatory state is associated with hemodynamic and cardiac changes due to excessive body weight and contributes to the increased likelihood of having heart failure for obese subjects [54].

3. Wound Healing

A wound is defined as a disruption in the normal continuity of the skin. When the skin is injured, a series of events takes place in order to close and heal the area where the barrier is compromised [55]. Wound healing is an evolutionary-conserved process comprised of four sequential yet overlapping phases: hemostasis, inflammation, proliferation and remodeling (see Figure 2) [56]. These phases are strictly regulated through specific molecules that are expressed at different levels at each time interval [57].
Life 13 00717 g002
Figure 2. Schematic representation of the wound healing process. While the wound heals and the injured area (in red) reduces, gradually leading to a scar, the four phases take place (from upper to lower panel): hemostasis, inflammation, proliferation and remodeling. The main cell types are indicated on the right and include: red blood cells and platelets (1), leucocytes and professional phagocytes (2), keratinocytes (3), endothelial cells (3), MSCs (3) and fibroblasts (3,4).
The first process that takes place in the unwinding of wound healing consists of coagulation and hemostasis, aimed at stopping the bleeding while creating a temporary matrix for cells to infiltrate the site of injury [58]. In fact, not only does vascular smooth muscle contraction reduce the diameter of injured vessels as a mechanism of reflex, but also activation of the coagulation cascade allows platelets to form a clot with fibronectin, fibrin, vitronectin and thrombospondin [59]. Platelets also release several growth factors and cytokines when degranulating [60]. Growth factors and cytokines such as PDGF (platelet-derived growth factor), TGFβ (transforming growth factor β) and EGF (epidermal growth factor) activate neutrophils, macrophages, endothelial cells, fibroblasts and keratinocytes [61]. Then comes the inflammatory phase, where neutrophils, monocytes and macrophages flood to the site of injury [62]. Neutrophils help in removing cell debris and microorganisms that may have slipped into the wound via phagocytosis [63]. Macrophages also enter the site not only as professional phagocytes but also as regulatory cells secreting TGFα and TGFβ, HB-EGF (heparin-binding epidermal growth factor), FGFs (fibroblast growth factor) and collagenases [64][65]. Partially overlapping with the inflammatory phase, the proliferation stage is characterized by the activation, expansion and migration of fibroblasts, keratinocytes and endothelial cells [66]. Proliferation also involves the production of collagen, proteoglycans, hyaluronic acid and other ECM structural proteins that, along with fibroblast recruitment, give rise to granulation tissue [67]. Moreover, endothelial cells aid in forming new vessels and thus epithelization takes place [68]. Cytokines and growth factors activate keratinocytes so that they can migrate from the edges of the wound over the dermal matrix in order to close up the wound [69]. The expression of specific keratins, such as K6 and K16, is observed in migrating keratinocytes [70]. Lastly, collagenases, matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are secreted by fibroblasts in the remodeling phase [65].

4. Obesity and Wound Healing

Wound healing seems to be impaired in obese patients compared to subjects with a normal BMI (body mass index), despite the mechanism underlying such a difference not being totally understood [71]. A multidisciplinary team is thus often essential for optimal wound care management in obese patients [72]. Decreased vascularization can partially explain wound healing delay [73]. In fact, the increase in the size of the adipocytes typical of obesity is generally not accompanied by an adequate rise in the number of vessels [74]. This eventually leads to a fibrotic environment [75], characterized by reduced elastin and increased collagen V and VI levels [76].
Wound healing disorders seem to have a huge impact in obese patients, both form a clinical and a social point of view. Venous insufficiency, caused or worsened by an elevated intra-abdominal pressure due to fat accumulation in the abdominal area [77], can cause leakage of proteinaceous-like material in the interstitial space, which can eventually occlude smaller vessels [78]. The resulting reduction in oxygen tension not only affects the proliferative and remodeling phases but also increases the risk of wound infection through the impairment of leukocyte phagocytic properties [12][79]. Arterial ulcers are associated to PAD, with atherosclerosis [72] being a well-known comorbidity in obese patients affected by metabolic syndrome [80] and/or T2D. Pressure ulcers are demonstrated to be common among obese patients staying in nursing homes [81]. However, contrasting data regarding the effects of obesity on the risk of development of pressure ulcers have been published so far in other patient subpopulations [82][83].
Peripheral neuropathy is another factor that can cause, aggravate or delay wound healing, and often represent the leading cause of cutaneous ulcers in diabetic patients [84][85]. Microangiopathy often represents the principal cause of impaired wound healing in T2D patients, leading to reduced nerve vascularization, endothelial dysfunction and impaired microcirculation [86]. On the other hand, macroangiopathy causes the production of prothrombotic factors and prevents the formation of an efficient network of collateral vessels, thus contributing to the pathogenesis of chronic wounds [87]. Finally, Advanced Glycation End-products (AGEs) appear to play a role in delaying wound healing in diabetic patients, affecting both angiogenesis and [88] extracellular matrix (ECM) production and remodeling [89]. Recent studies have demonstrated insulin to promote cell migration, and insulin-based therapies have therefore been suggested to surmount the impact of insulin resistance on wound repairing [89][90]. In addition, leptin, an anti-obesity hormone, improves wound repairing by accelerating angiogenesis and promoting the proliferation, differentiation and migration of keratinocytes [91]. Leptin is physiologically produced by adipocytes and leads to a reduction in the caloric intake, regulating body weight. Nevertheless, a high-fat diet leads to a leptin-resistant condition over time, thus limiting the effects of this hormone [92]. In obese patients, high leptin plasma levels are associated with peripheral receptor resistance [93].

References

  1. Deitel, M. Overweight and Obesity Worldwide Now Estimated to Involve 1.7 Billion People. Obes. Surg. 2003, 13, 329–330.
  2. Baghbani-Naghadehi, F.; Armijo-Olivo, S.; Prado, C.M.; Woodhouse, L.J. Obesity, Comorbidities, and the Associated Risk among Patients Who Underwent Total Knee Arthroplasty in Alberta. J. Knee Surg. 2022, s-0042-1742646.
  3. Ligi, D.; Croce, L.; Mosti, G.; Raffetto, J.D.; Mannello, F. Chronic Venous Insufficiency: Transforming Growth Factor-β Isoforms and Soluble Endoglin Concentration in Different States of Wound Healing. Int. J. Mol. Sci. 2017, 18, 2206.
  4. Moss, J.-L.; Pugliese, M.; Richards, T. Ultrasound Patterns of Venous Disease in Patients with Venous Leg Ulcers and Morbid Obesity. Phlebology 2022, 37, 732–738.
  5. Costa, D.; Andreucci, M.; Ielapi, N.; Serraino, G.F.; Mastroroberto, P.; Bracale, U.M.; Serra, R. Molecular Determinants of Chronic Venous Disease: A Comprehensive Review. Int. J. Mol. Sci. 2023, 24, 1928.
  6. Dayya, D.; O’Neill, O.J.; Huedo-Medina, T.B.; Habib, N.; Moore, J.; Iyer, K. Debridement of Diabetic Foot Ulcers. Adv. Wound Care 2022, 11, 666–686.
  7. Luo, R.; Ji, Y.; Liu, Y.-H.; Sun, H.; Tang, S.; Li, X. Relationships among Social Support, Coping Style, Self-Stigma, and Quality of Life in Patients with Diabetic Foot Ulcer: A Multicentre, Cross-Sectional Study. Int. Wound J. 2023, 20, 716–724.
  8. Jung, F.U.C.E.; Riedel-Heller, S.G.; Luck-Sikorski, C. The Relationship between Weight History and Psychological Health-Differences Related to Gender and Weight Loss Patterns. PLoS ONE 2023, 18, e0281776.
  9. Giralt, M.; Villarroya, F. White, Brown, Beige/Brite: Different Adipose Cells for Different Functions? Endocrinology 2013, 154, 2992–3000.
  10. Li, J.; Xu, R. Obesity-Associated ECM Remodeling in Cancer Progression. Cancers 2022, 14, 5684.
  11. Esteve Ràfols, M. Adipose Tissue: Cell Heterogeneity and Functional Diversity. Endocrinol. Nutr. 2014, 61, 100–112.
  12. Pierpont, Y.N.; Dinh, T.P.; Salas, R.E.; Johnson, E.L.; Wright, T.G.; Robson, M.C.; Payne, W.G. Obesity and Surgical Wound Healing: A Current Review. ISRN Obes. 2014, 2014, 638936.
  13. Friedman, A.; Siewe, N. Mathematical Model of Chronic Dermal Wounds in Diabetes and Obesity. Bull. Math. Biol. 2020, 82, 137.
  14. Shook, B.A.; Wasko, R.R.; Mano, O.; Rutenberg-Schoenberg, M.; Rudolph, M.C.; Zirak, B.; Rivera-Gonzalez, G.C.; López-Giráldez, F.; Zarini, S.; Rezza, A.; et al. Dermal Adipocyte Lipolysis and Myofibroblast Conversion Are Required for Efficient Skin Repair. Cell Stem Cell 2020, 26, 880–895.e6.
  15. Rawal, K.; Patel, T.P.; Purohit, K.M.; Israni, K.; Kataria, V.; Bhatt, H.; Gupta, S. Influence of Obese Phenotype on Metabolic Profile, Inflammatory Mediators and Stemness of HADSC in Adipose Tissue. Clin. Nutr. 2020, 39, 3829–3835.
  16. Paganelli, A.; Benassi, L.; Rossi, E.; Tarentini, E.; Magnoni, C. Mesenchymal Stromal Cells Promote the Proliferation of Basal Stem Cells and Efficient Epithelization in Organotypic Models of Wound Healing. Microsc. Res. Tech. 2022, 85, 2752–2756.
  17. García-Gómez, I.; Elvira, G.; Zapata, A.G.; Lamana, M.L.; Ramírez, M.; Castro, J.G.; Arranz, M.G.; Vicente, A.; Bueren, J.; García-Olmo, D. Mesenchymal Stem Cells: Biological Properties and Clinical Applications. Expert Opin. Biol. Ther. 2010, 10, 1453–1468.
  18. Villagrasa, A.; Posada-González, M.; García-Arranz, M.; Zapata, A.G.; Vorwald, P.; Olmedillas-López, S.; Vega-Clemente, L.; García-Olmo, D. Implicación de las células madre derivadas del tejido adiposo en la cicatrización de heridas de pacientes obesos y pacientes oncológicos. CIRU 2022, 90, 6528.
  19. Paganelli, A.; Benassi, L.; Pastar, I.; Pellegrini, M.; Azzoni, P.; Vaschieri, C.; Pisciotta, A.; Carnevale, G.; Pellacani, G.; Magnoni, C. In Vitro Engineering of a Skin Substitute Based on Adipose-Derived Stem Cells. Cells Tissues Organs 2019, 207, 46–57.
  20. Pachón-Peña, G.; Serena, C.; Ejarque, M.; Petriz, J.; Duran, X.; Oliva-Olivera, W.; Simó, R.; Tinahones, F.J.; Fernández-Veledo, S.; Vendrell, J. Obesity Determines the Immunophenotypic Profile and Functional Characteristics of Human Mesenchymal Stem Cells From Adipose Tissue. Stem Cells Transl. Med. 2016, 5, 464–475.
  21. De Assis-Ferreira, A.; Saldanha-Gama, R.; de Brito, N.M.; Renovato-Martins, M.; Simões, R.L.; Barja-Fidalgo, C.; Vargas da Silva, S. Obesity Enhances the Recruitment of Mesenchymal Stem Cells to Visceral Adipose Tissue. J. Mol. Endocrinol. 2021, 67, 15–26.
  22. Pluta, W.; Dudzińska, W.; Lubkowska, A. Metabolic Obesity in People with Normal Body Weight (MONW)-Review of Diagnostic Criteria. Int. J. Environ. Res. Public Health 2022, 19, 624.
  23. Ahmed, B.; Sultana, R.; Greene, M.W. Adipose Tissue and Insulin Resistance in Obese. Biomed. Pharmacother. 2021, 137, 111315.
  24. Longo, M.; Zatterale, F.; Naderi, J.; Parrillo, L.; Formisano, P.; Raciti, G.A.; Beguinot, F.; Miele, C. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int. J. Mol. Sci. 2019, 20, 2358.
  25. Nam, G.E.; Park, H.S. Perspective on Diagnostic Criteria for Obesity and Abdominal Obesity in Korean Adults. JOMES 2018, 27, 134–142.
  26. Hyde, R. Europe Battles with Obesity. Lancet 2008, 371, 2160–2161.
  27. Żukiewicz-Sobczak, W.; Wróblewska, P.; Zwoliński, J.; Chmielewska-Badora, J.; Adamczuk, P.; Krasowska, E.; Zagórski, J.; Oniszczuk, A.; Piątek, J.; Silny, W. Obesity and Poverty Paradox in Developed Countries. Ann. Agric. Environ. Med. 2014, 21, 590–594.
  28. Héraïef, E. The contribution of epidemiology to the definition of obesity and its risk factors. Ther. Umsch. 1989, 46, 275–280.
  29. Levine, J.A. Poverty and Obesity in the U.S. Diabetes 2011, 60, 2667–2668.
  30. Avenell, A.; Broom, J.; Brown, T.J.; Poobalan, A.; Aucott, L.; Stearns, S.C.; Smith, W.C.S.; Jung, R.T.; Campbell, M.K.; Grant, A.M. Systematic Review of the Long-Term Effects and Economic Consequences of Treatments for Obesity and Implications for Health Improvement. Health Technol. Assess. 2004, 8, iii–iv, 1–182.
  31. Finkelstein, E.A.; Trogdon, J.G.; Cohen, J.W.; Dietz, W. Annual Medical Spending Attributable to Obesity: Payer-and Service-Specific Estimates. Health Aff. 2009, 28, w822–w831.
  32. Van den Broek-Altenburg, E.; Atherly, A.; Holladay, E. Changes in Healthcare Spending Attributable to Obesity and Overweight: Payer- and Service-Specific Estimates. BMC Public Health 2022, 22, 962.
  33. Guillaume, M.; Lapidus, L.; Beckers, F.; Lambert, A.; Björntorp, P. Familial Trends of Obesity through Three Generations: The Belgian-Luxembourg Child Study. Int. J. Obes. Relat. Metab. Disord. 1995, 19, S5–S9.
  34. Grio, R.; Porpiglia, M. Obesity: Internal Medicine, Obstetric and Gynecological Problems Related to Overweight. Panminerva Med. 1994, 36, 138–141.
  35. Flegal, K.M.; Troiano, R.P.; Pamuk, E.R.; Kuczmarski, R.J.; Campbell, S.M. The Influence of Smoking Cessation on the Prevalence of Overweight in the United States. N. Engl. J. Med. 1995, 333, 1165–1170.
  36. Parsons, T.J.; Power, C.; Logan, S.; Summerbell, C.D. Childhood Predictors of Adult Obesity: A Systematic Review. Int. J. Obes. Relat. Metab. Disord. 1999, 23, S1–S107.
  37. Mauras, N.; Delgiorno, C.; Kollman, C.; Bird, K.; Morgan, M.; Sweeten, S.; Balagopal, P.; Damaso, L. Obesity without Established Comorbidities of the Metabolic Syndrome Is Associated with a Proinflammatory and Prothrombotic State, Even before the Onset of Puberty in Children. J. Clin. Endocrinol. Metab. 2010, 95, 1060–1068.
  38. Ziogas, I.A.; Zapsalis, K.; Giannis, D.; Tsoulfas, G. Metabolic Syndrome and Liver Disease in the Era of Bariatric Surgery: What You Need to Know! World J. Hepatol. 2020, 12, 709–721.
  39. Schienkiewitz, A.; Schulze, M.B.; Hoffmann, K.; Kroke, A.; Boeing, H. Body Mass Index History and Risk of Type 2 Diabetes: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam Study. Am. J. Clin. Nutr. 2006, 84, 427–433.
  40. Samad, F.; Ruf, W. Inflammation, Obesity, and Thrombosis. Blood 2013, 122, 3415–3422.
  41. Reaven, G.M. Insulin Resistance: The Link Between Obesity and Cardiovascular Disease. Med. Clin. N. Am. 2011, 95, 875–892.
  42. Rocha, V.Z.; Libby, P. Obesity, Inflammation, and Atherosclerosis. Nat. Rev. Cardiol. 2009, 6, 399–409.
  43. Zaman, C.F.; Sultana, J.; Dey, P.; Dutta, J.; Mustarin, S.; Tamanna, N.; Roy, A.; Bhowmick, N.; Khanam, M.; Sultana, S.; et al. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review. Cureus 2022, 14, e29657.
  44. Kyrou, I.; Randeva, H.S.; Tsigos, C.; Kaltsas, G.; Weickert, M.O. Clinical Problems Caused by Obesity. In Endotext; Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Hofland, J., Dungan, K., et al., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000.
  45. Yue, W.; Huang, X.; Zhang, W.; Li, S.; Liu, X.; Zhao, Y.; Shu, J.; Liu, T.; Li, W.; Liu, S. Metabolic Surgery on Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front. Endocrinol. 2022, 13, 848947.
  46. Lauby-Secretan, B.; Scoccianti, C.; Loomis, D.; Grosse, Y.; Bianchini, F.; Straif, K. International Agency for Research on Cancer Handbook Working Group Body Fatness and Cancer—Viewpoint of the IARC Working Group. N. Engl. J. Med. 2016, 375, 794–798.
  47. Zhou, L.; Li, J.; Ontaneda, D.; Sperling, J. Metabolic Syndrome in Small Fiber Sensory Neuropathy. J. Clin. Neuromuscul. Dis. 2011, 12, 235–243.
  48. For the Alzheimer’s Disease Neuroimaging Initiative; Morys, F.; Potvin, O.; Zeighami, Y.; Vogel, J.; Lamontagne-Caron, R.; Duchesne, S.; Dagher, A. Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer’s Disease in an Observational Cohort Study. J. Alzheimers Dis. 2023, 91, 1059–1071.
  49. Tobin, A.-M.; Ahern, T.; Rogers, S.; Collins, P.; O’Shea, D.; Kirby, B. The Dermatological Consequences of Obesity: Dermatological Consequences of Obesity. Int. J. Dermatol. 2013, 52, 927–932.
  50. Sebastian, J.C. Respiratory Physiology and Pulmonary Complications in Obesity. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 157–161.
  51. Kivimäki, M.; Batty, G.D.; Singh-Manoux, A.; Nabi, H.; Sabia, S.; Tabak, A.G.; Akbaraly, T.N.; Vahtera, J.; Marmot, M.G.; Jokela, M. Association between Common Mental Disorder and Obesity over the Adult Life Course. Br. J. Psychiatry 2009, 195, 149–155.
  52. Mohamed-Ali, V.; Goodrick, S.; Rawesh, A.; Katz, D.R.; Miles, J.M.; Yudkin, J.S.; Klein, S.; Coppack, S.W. Subcutaneous Adipose Tissue Releases Interleukin-6, but Not Tumor Necrosis Factor-Alpha, in Vivo. J. Clin. Endocrinol. Metab. 1997, 82, 4196–4200.
  53. Bastard, J.P.; Jardel, C.; Delattre, J.; Hainque, B.; Bruckert, E.; Oberlin, F. Evidence for a Link between Adipose Tissue Interleukin-6 Content and Serum C-Reactive Protein Concentrations in Obese Subjects. Circulation 1999, 99, 2221–2222.
  54. Bozkurt, B.; Aguilar, D.; Deswal, A.; Dunbar, S.B.; Francis, G.S.; Horwich, T.; Jessup, M.; Kosiborod, M.; Pritchett, A.M.; Ramasubbu, K.; et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016, 134, e535–e578.
  55. Pastar, I.; Stojadinovic, O.; Yin, N.C.; Ramirez, H.; Nusbaum, A.G.; Sawaya, A.; Patel, S.B.; Khalid, L.; Isseroff, R.R.; Tomic-Canic, M. Epithelialization in Wound Healing: A Comprehensive Review. Adv. Wound Care 2014, 3, 445–464.
  56. Broszczak, D.A.; Sydes, E.R.; Wallace, D.; Parker, T.J. Molecular Aspects of Wound Healing and the Rise of Venous Leg Ulceration: Omics Approaches to Enhance Knowledge and Aid Diagnostic Discovery. Clin. Biochem. Rev. 2017, 38, 35–55.
  57. Eming, S.A.; Martin, P.; Tomic-Canic, M. Wound Repair and Regeneration: Mechanisms, Signaling, and Translation. Sci. Transl. Med. 2014, 6, 265sr6.
  58. Velnar, T.; Bailey, T.; Smrkolj, V. The Wound Healing Process: An Overview of the Cellular and Molecular Mechanisms. J. Int. Med. Res. 2009, 37, 1528–1542.
  59. Gurtner, G.C.; Werner, S.; Barrandon, Y.; Longaker, M.T. Wound Repair and Regeneration. Nature 2008, 453, 314–321.
  60. Żurawska-Płaksej, E.; Kuliczkowski, W.; Karolko, B.; Cielecka-Prynda, M.; Dębski, J.; Kaaz, K.; Mysiak, A.; Wróbel, T.; Podolak-Dawidziak, M.; Usnarska-Zubkiewicz, L. Platelet Polyphosphate Level Is Elevated in Patients with Chronic Primary Thrombocytopenia: A Preliminary Study. Adv. Clin. Exp. Med. 2020, 29, 1051–1056.
  61. Werner, S.; Grose, R. Regulation of Wound Healing by Growth Factors and Cytokines. Physiol. Rev. 2003, 83, 835–870.
  62. Zhao, G.; Usui, M.L.; Lippman, S.I.; James, G.A.; Stewart, P.S.; Fleckman, P.; Olerud, J.E. Biofilms and Inflammation in Chronic Wounds. Adv. Wound Care 2013, 2, 389–399.
  63. Eming, S.A.; Krieg, T.; Davidson, J.M. Inflammation in Wound Repair: Molecular and Cellular Mechanisms. J. Investig. Dermatol. 2007, 127, 514–525.
  64. Qiang, L.; Yang, S.; Cui, Y.-H.; He, Y.-Y. Keratinocyte Autophagy Enables the Activation of Keratinocytes and Fibroblastsand Facilitates Wound Healing. Autophagy 2021, 17, 2128–2143.
  65. Stricklin, G.P.; Li, L.; Jancic, V.; Wenczak, B.A.; Nanney, L.B. Localization of MRNAs Representing Collagenase and TIMP in Sections of Healing Human Burn Wounds. Am. J. Pathol. 1993, 143, 1657–1666.
  66. Harding, K.G.; Morris, H.L.; Patel, G.K. Science, Medicine and the Future: Healing Chronic Wounds. BMJ 2002, 324, 160–163.
  67. Zheng, Y.; Xu, P.; Pan, C.; Wang, Y.; Liu, Z.; Chen, Y.; Chen, C.; Fu, S.; Xue, K.; Zhou, Q.; et al. Production and Biological Effects of Extracellular Vesicles from Adipose-Derived Stem Cells Were Markedly Increased by Low-Intensity Ultrasound Stimulation for Promoting Diabetic Wound Healing. Stem Cell Rev. Rep. 2022, 1–23.
  68. Zwaginga, J.J.; Doevendans, P. Stem Cell-Derived Angiogenic/Vasculogenic Cells: Possible Therapies for Tissue Repair and Tissue Engineering. Clin. Exp. Pharmacol. Physiol. 2003, 30, 900–908.
  69. Pilcher, B.K.; Wang, M.; Qin, X.-J.; Parks, W.C.; Senior, R.M.; Welgus, H.G. Role of Matrix Metalloproteinases and Their Inhibition in Cutaneous Wound Healing and Allergic Contact Hypersensitivity. Ann. N. Y. Acad. Sci. 1999, 878, 12–24.
  70. Stojadinovic, O.; Brem, H.; Vouthounis, C.; Lee, B.; Fallon, J.; Stallcup, M.; Merchant, A.; Galiano, R.D.; Tomic-Canic, M. Molecular Pathogenesis of Chronic Wounds: The Role of Beta-Catenin and c-Myc in the Inhibition of Epithelialization and Wound Healing. Am. J. Pathol. 2005, 167, 59–69.
  71. Gallagher Camden, S.; Gates, J. Obesity: Changing the Face of Geriatric Care. Ostomy Wound Manag. 2006, 52, 36–38, 40–44.
  72. Schneider, C.; Stratman, S.; Kirsner, R.S. Lower Extremity Ulcers. Med. Clin. N. Am. 2021, 105, 663–679.
  73. Lazar, M.; Ershadi, S.; Bolton, L.; Phillips, T. Patient-Centered Outcomes for Individuals with a Venous Leg Ulcer: A Scoping Review. Adv. Ski. Wound Care 2023, 36, 10–17.
  74. Corvera, S.; Solivan-Rivera, J.; Yang Loureiro, Z. Angiogenesis in Adipose Tissue and Obesity. Angiogenesis 2022, 25, 439–453.
  75. Khan, T.; Muise, E.S.; Iyengar, P.; Wang, Z.V.; Chandalia, M.; Abate, N.; Zhang, B.B.; Bonaldo, P.; Chua, S.; Scherer, P.E. Metabolic Dysregulation and Adipose Tissue Fibrosis: Role of Collagen VI. Mol. Cell. Biol. 2009, 29, 1575–1591.
  76. Spencer, M.; Unal, R.; Zhu, B.; Rasouli, N.; McGehee, R.E.; Peterson, C.A.; Kern, P.A. Adipose Tissue Extracellular Matrix and Vascular Abnormalities in Obesity and Insulin Resistance. J. Clin. Endocrinol. Metab. 2011, 96, E1990–E1998.
  77. Stadelmann, W.K.; Digenis, A.G.; Tobin, G.R. Impediments to Wound Healing. Am. J. Surg. 1998, 176, 39S–47S.
  78. Yosipovitch, G.; DeVore, A.; Dawn, A. Obesity and the Skin: Skin Physiology and Skin Manifestations of Obesity. J. Am. Acad. Dermatol. 2007, 56, 901–916.
  79. Robson, M.C. Wound infection. Surg. Clin. N. Am. 1997, 77, 637–650.
  80. Yu, M.; Zhang, S.; Wang, L.; Wu, J.; Li, X.; Yuan, J. Metabolically Healthy Obesity and Carotid Plaque among Steelworkers in North China: The Role of Inflammation. Nutrients 2022, 14, 5123.
  81. Cai, S.; Rahman, M.; Intrator, O. Obesity and Pressure Ulcers among Nursing Home Residents. Med. Care 2013, 51, 478–486.
  82. Alipoor, E.; Mehrdadi, P.; Yaseri, M.; Hosseinzadeh-Attar, M.J. Association of Overweight and Obesity with the Prevalence and Incidence of Pressure Ulcers: A Systematic Review and Meta-Analysis. Clin. Nutr. 2021, 40, 5089–5098.
  83. Großschädl, F.; Bauer, S. The Relationship between Obesity and Nursing Care Problems in Intensive Care Patients in Austria. Nurs. Crit. Care 2022, 27, 512–518.
  84. Boulton, A.J.M.; Whitehouse, R.W. The Diabetic Foot. In Endotext; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., Kalra, S., et al., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000.
  85. Andrews, K.L.; Dyck, P.J.; Kavros, S.J.; Vella, A.; Kazamel, M.; Clark, V.; Litchy, W.J.; Dyck, P.J.B.; Lodermeier, K.A.; Davies, J.L.; et al. Plantar Ulcers and Neuropathic Arthropathies: Associated Diseases, Polyneuropathy Correlates, and Risk Covariates. Adv. Ski. Wound Care 2019, 32, 168–175.
  86. Costa, D.; Ielapi, N.; Caprino, F.; Giannotta, N.; Sisinni, A.; Abramo, A.; Ssempijja, L.; Andreucci, M.; Bracale, U.M.; Serra, R. Social Aspects of Diabetic Foot: A Scoping Review. Soc. Sci. 2022, 11, 149.
  87. Ackermann, P.W.; Hart, D.A. Influence of Comorbidities: Neuropathy, Vasculopathy, and Diabetes on Healing Response Quality. Adv. Wound Care 2013, 2, 410–421.
  88. Peppa, M.; Raptis, S.A. Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship. Curr. Diabetes Rev. 2011, 7, 416–425.
  89. Strollo, F.; Gentile, S.; Pipicelli, A.M.V.; Mambro, A.; Monici, M.; Magni, P. Space Flight-Promoted Insulin Resistance as a Possible Disruptor of Wound Healing. Front. Bioeng. Biotechnol. 2022, 10, 868999.
  90. Yang, P.; Pei, Q.; Yu, T.; Chang, Q.; Wang, D.; Gao, M.; Zhang, X.; Liu, Y. Compromised Wound Healing in Ischemic Type 2 Diabetic Rats. PLoS ONE 2016, 11, e0152068.
  91. Tadokoro, S.; Ide, S.; Tokuyama, R.; Umeki, H.; Tatehara, S.; Kataoka, S.; Satomura, K. Leptin Promotes Wound Healing in the Skin. PLoS ONE 2015, 10, e0121242.
  92. Fam, B.C.; Morris, M.J.; Hansen, M.J.; Kebede, M.; Andrikopoulos, S.; Proietto, J.; Thorburn, A.W. Modulation of Central Leptin Sensitivity and Energy Balance in a Rat Model of Diet-Induced Obesity. Diabetes Obes. Metab. 2007, 9, 840–852.
  93. Dopytalska, K.; Baranowska-Bik, A.; Roszkiewicz, M.; Bik, W.; Walecka, I. The Role of Leptin in Selected Skin Diseases. Lipids Health Dis. 2020, 19, 215.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Dermatology; Nutrition & Dietetics; Medicine, Research & Experimental
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Antonio Alma
,
Guya Diletta Marconi
,
Elena Rossi
,
Cristina Magnoni
,
Alessia Paganelli
View Times: 677
Revisions: 2 times (View History)
Update Date: 24 Mar 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback